Skip to content

Can a wild green oat extract enhance attention and concentration in adults under demanding conditions?

Effects of Neuravena 'registered trade mark' (wild oat extract) on high demand cognitive performance, cerebral blood flow, blood pressure responses, psychological well-being in healthy Australian adults aged over 60 years

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12610000012077
Enrollment
37
Registered
2010-01-06
Start date
2010-03-01
Completion date
2010-04-30
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Avena sativa (oats), in its various forms and extracts, has been traditionally known for its physical and psychological fortifying properties. Proposed beneficial effects include: reduced risk of heart disease, raised energy levels, increased ability to cope with stress, reduced anxiety and depression, and increased physical and cognitive performance. The mechanism of effect is currently unknown. However, it has been suggested that some ingredient(s) found in green oats have clinically significant inhibitory effects on monoamine oxidase B (MAO-B) and phosphodiesterase 4 (PDE4), effects which may improve cerebral vasodilatation. As enhancement of cerebral blood flow by vasoactive nutrients has been hypothesised to improve cognitive function, this may be the mechanism by which oat extract could improve cognitive performance and stress response. The aim of this study is to examine the effect of daily consumption of Neuravena for 12 weeks on the ability to cope with stressful cognitive tasks, cognitive performance and on psychological well-being (mood) and whether these effects are mediated by changes in cerebral blood flow.

Interventions

Volunteers will consume a 1500mg dose of Avena sativa extract (Neuravena 'registered trade mark') daily for 12 weeks. This supplement will be delivered orally in capsule form. Subjects will have three separate visits to the Nutritional Physiology Research Centre (of 2 hours duration each). Following a baseline visit they will be randomised to consume a placebo or a 1500mg dose of Neuravena 'registered trade mark' for 12 weeks, after which they will cross over to the alternate treatment. The visi

Volunteers will consume a 1500mg dose of Avena sativa extract (Neuravena 'registered trade mark') daily for 12 weeks. This supplement will be delivered orally in capsule form. Subjects will have three separate visits to the Nutritional Physiology Research Centre (of 2 hours duration each). Following a baseline visit they will be randomised to consume a placebo or a 1500mg dose of Neuravena 'registered trade mark' for 12 weeks, after which they will cross over to the alternate treatment. The visits will 12 weeks apart. The time between the final measurement on the first supplement and first measurement after the crossover will be 12 weeks, this will serve as the washout period. At each visit resting supine clinic blood pressure will be measured following internationally recognised guidelines. This will be followed by measurement of cerebral blood flow during a carbon dioxide (CO2) challenge. Participants will then perform tests of attention, concentration, the ability to ignore distraction and to inhibit task-irrelevant information, namely the Stroop test, the Letter Cancellation task, the Rule Shift task, the Trail-Making test, the Dual Span Memory Task, and a multitasking Computerised Battery. Current mood will be assessed using Visual Analogue Scales, the mood states include: relaxed, alert, jittery, tired, tense, headache, mental fatigue and overall mood. These measures will be repeated at each visit.

Sponsors

Dr. Janet Bryan
Lead SponsorIndividual

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Prevention
Masking
Blinded (masking used)

Eligibility

Sex/Gender
All
Age
60 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Healthy men and women aged over 60 years

Exclusion criteria

Taking any form of cognitive enhancers, anticholinergic medication or mood medication during the trial, have a history of serious head injury, diagnosed and/or treated mental illness, alcoholism, stroke and/or neurological condition, suspected dementia as determined by Dem TECT (score less than 9), dyslexia, colourblindness, unable to perform transcranial Doppler assessment at baseline, cardiovascular, renal or gastrointestinal disease, diabetes, recent changes (last 3 months) in blood pressure (BP) lowering medication, resting supine blood pressure of >160/100 mmHg, regular consumption of oats (greater than one serve per day), smokers or those using nicotine replacement therapy will also be excluded, and any other medical condition or treatments (including supplements) which, in the opinion of the investigators, may influence the outcome of the study

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026